JARDIANCE® Post Marketing Surveillance in Korean Patients With Chronic Kidney Disease (CKD)
N/A
Completed
NCT06287073
| Condition | Kidney Disease, Chronic |
|---|
| Phase | N/A |
|---|
| Sponsor | Boehringer Ingelheim |
|---|
| Status | Completed |
|---|
| Enrollment | 299 participants |
|---|
| Interventions | JARDIANCE® |
|---|
| Start date | Mar 29, 2024 |
|---|
| Completion date | Apr 30, 2025 |
|---|
| Results posted | Jun 23, 2026 |
|---|
Summary
The primary objective is to monitor the safety profile of JARDIANCE® in Korean patient with chronic kidney disease (CKD) in routine clinical practice. The secondary objective is to monitor the efficacy of JARDIANCE® by evaluating changes in urine albumin-creatinine ratio (UACR) after 12 and/or 24 weeks of treatment.
Number of Participants With Adverse Events (AEs)
Up to 337 days. · Participants
| JARDIANCE® Treated Patients | 46 Participants |
|---|
Number of Participants With Serious Adverse Event (SAEs)
Up to 337 days. · Participants
| JARDIANCE® Treated Patients | 6 Participants |
|---|
Number of Participants With Non-serious Adverse Events
Up to 337 days. · Participants
| JARDIANCE® Treated Patients | 42 Participants |
|---|
Open in BENITIONS
View on ClinicalTrials.gov
All trials
This page summarises publicly available data from ClinicalTrials.gov. It is not medical advice and not investment advice. Always consult a qualified healthcare professional.